PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
7913199-8	1994	Parallel tests with beta-adrenergic antagonists revealed that the potentiation by isoproterenol could be significantly diminished by a single dose of the non-selective beta-adrenoreceptor blocking drug nadolol or the beta 2-selective antagonist ICI-118,551, but not the beta 1-selective antagonist metoprolol.	Nadolol	202-209	hemoglobin, beta adult major chain	Mus musculus	270-276
12959274-9	1993	6 A similar pattern to Raw was observed for both of the beta2-mediated metabolic responses which were also antagonised by nadolol.	Nadolol	122-129	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	56-61
8255974-3	1993	They were pretreated with either placebo, 25 mg atenolol (a selective beta 1 antagonist), or 5, 20 and 80 mg nadolol (which blocks beta 1 and beta 2 but not beta 3-adrenoceptors).	Nadolol	109-116	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	131-148
8255974-5	1993	Significant beta 2-blockade (from tremor data) occurred with 5 mg nadolol but not with 25 mg atenolol.	Nadolol	66-73	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	12-18
8255974-7	1993	However, the rise in BMR was not totally blocked even by 80 mg nadolol (9.5%), which produced complete beta 1/beta 2 blockade, as evidenced by the elimination of the chronotropic effect of isoprenaline.	Nadolol	63-70	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	103-116
8392210-5	1993	Nadolol 5 mg produced almost complete blunting of finger tremor (beta 2-blockade) whilst atenolol 25 mg had no significant effect.	Nadolol	0-7	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	65-71
1504370-4	1992	Spleen cells from rats treated with nadolol, a peripherally acting beta-adrenergic receptor antagonist, and then shocked, showed dose-dependent attenuation of the suppression of interferon-gamma production.	Nadolol	36-43	interferon gamma	Rattus norvegicus	178-194
1877672-6	1991	Combined muscarinic-cholinergic (atropine; 0.11 mg/kg iv) and beta-adrenergic receptor blockade (nadolol; 0.5 mg/kg iv) abolished the stimulatory effects of ISO on subsidiary atrial and atrioventricular junctional pacemakers but did not affect the responses to VIP.	Nadolol	97-104	vasoactive intestinal peptide	Canis lupus familiaris	261-264
2380655-4	1990	Both sarcosine-isoleucine-angiotensin II ([Sar, Ile]-ANG II) and atropine blocked, and nadolol increased, the effect of EFS and exogenous angiotensin II on serotonin production.	Nadolol	87-94	angiotensinogen	Rattus norvegicus	138-152
2380655-5	1990	Nadolol blocked both the EFS-induced and the angiotensin II-induced production of melatonin.	Nadolol	0-7	angiotensinogen	Rattus norvegicus	45-59
33798116-0	2021	Stability of Extemporaneously Compounded Nadolol 10-mg/mL Suspension in Oral Mix in Glass and Plastic Bottles and Plastic Syringes.	Nadolol	41-48	Mix paired-like homeobox	Homo sapiens	77-80
33798116-2	2021	The objective of this study was to evaluate the stability of nadolol 10 mg/mL prepared in Oral Mix vehicle and stored in amber glass, amber polyethylene terephthalate, or amber polyvinyl chloride for 91 days at 4AEC and 25AEC; and polypropylene oral plastic syringes at 25AEC only.	Nadolol	61-68	Mix paired-like homeobox	Homo sapiens	95-98
33798116-3	2021	Three separate batches of nadolol suspension 10 mg/mL were prepared with Oral Mix.	Nadolol	26-33	Mix paired-like homeobox	Homo sapiens	78-81
33798116-8	2021	The concentration of nadolol 10 mg/mL in Oral Mix in all study samples from bottles and oral syringes remained within 3.5% of the initial concentration.	Nadolol	21-28	Mix paired-like homeobox	Homo sapiens	46-49
33798116-12	2021	On day 91, nadolol 10 mg/mL oral suspensions prepared with Oral Mix and stored in all bottle types at 4AEC will retain more than 98% of the initial concentration compared to 99% at 25AEC and only 94% when stored in oral syringes.	Nadolol	11-18	Mix paired-like homeobox	Homo sapiens	64-67
34303263-15	2021	Our data suggest that the reduced nadolol bioavailability is associated with the downregulation of ileal Oatp1a5 and Oct1 mRNA levels that subsequently lead to poor absorption of nadolol to the systemic circulation.	Nadolol	34-41	solute carrier family 22 member 1	Rattus norvegicus	117-121
34303263-15	2021	Our data suggest that the reduced nadolol bioavailability is associated with the downregulation of ileal Oatp1a5 and Oct1 mRNA levels that subsequently lead to poor absorption of nadolol to the systemic circulation.	Nadolol	179-186	solute carrier family 22 member 1	Rattus norvegicus	117-121
34425806-5	2021	The activity of beta-ARs was modulated by an agonist, norepinephrine (NE), and antagonists, including propranolol, atenolol, nebivolol, and nadolol.	Nadolol	140-147	alanyl-tRNA synthetase 1	Homo sapiens	16-24
34425806-7	2021	Treatment of chondrocytes with IL-1beta and beta-blockers, including propranolol, atenolol, nebivolol, and nadolol, for 6 h significantly upregulated IL-1beta-induced expression of MMP-1, -3, and - 13, compared to chondrocytes treated with IL-1beta alone, indicating that antagonism of beta-AR confers catabolic signals.	Nadolol	107-114	interleukin 1 alpha	Homo sapiens	31-39
34425806-7	2021	Treatment of chondrocytes with IL-1beta and beta-blockers, including propranolol, atenolol, nebivolol, and nadolol, for 6 h significantly upregulated IL-1beta-induced expression of MMP-1, -3, and - 13, compared to chondrocytes treated with IL-1beta alone, indicating that antagonism of beta-AR confers catabolic signals.	Nadolol	107-114	interleukin 1 alpha	Homo sapiens	150-158
34425806-7	2021	Treatment of chondrocytes with IL-1beta and beta-blockers, including propranolol, atenolol, nebivolol, and nadolol, for 6 h significantly upregulated IL-1beta-induced expression of MMP-1, -3, and - 13, compared to chondrocytes treated with IL-1beta alone, indicating that antagonism of beta-AR confers catabolic signals.	Nadolol	107-114	matrix metallopeptidase 1	Homo sapiens	181-200
34326250-8	2021	We exemplified our quantification method using beta1AR and demonstrated the allosteric effect of Nb80 binding in assisting displacement of nadolol to isoprenaline.	Nadolol	139-146	adrenoceptor beta 1	Homo sapiens	47-54
34901807-1	2021	A novel frameshift mutation in the KCNH2 gene for long QT syndrome type 2 (LQTS2) was identified after torsades des pointes ventricular tachycardia in a 49-year-old patient managed with octreotide and nadolol for an acute variceal bleed.	Nadolol	201-208	potassium voltage-gated channel subfamily H member 2	Homo sapiens	35-40
2663317-5	1989	With increasing nadolol doses, plasma norepinephrine concentration increased and isoproterenol sensitivity decreased in both young and elderly subjects, and creatinine clearance and plasma active renin levels were unchanged; plasma inactive renin levels increased in the young, and aldosterone concentration declined in the elderly with the lowest nadolol dose.	Nadolol	16-23	renin	Homo sapiens	241-246
2521058-4	1989	Thereafter, either pharmacologically inert, artificial CSF or nadolol was introduced through transcerebral, intraventricular perfusion with a significant reduction in aggression in the nadolol-treated animals when compared with those receiving artificial CSF.	Nadolol	185-192	colony stimulating factor 2	Rattus norvegicus	55-58
2901435-5	1988	This result established that the dose ratio of cetamolol:atenolol:nadolol of 1.00:3.33:2.67 provides equipotent beta-1 blockade.	Nadolol	66-73	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	112-118
2845445-6	1988	The behaviorally suppressive effects of either 0.4 mg/kg isoproterenol or 0.05 mg/kg clenbuterol were found to be completely antagonized by pretreatment with a 10.0 mg/kg dose of nadolol, a beta antagonist that does not penetrate the brain when administered systemically.	Nadolol	179-186	amyloid beta precursor protein	Rattus norvegicus	188-194
2875812-3	1986	Subjects randomly assigned to receive placebo, 50 mg bid atenolol, or 40 mg bid nadolol were tested before and after training both on and off drugs.	Nadolol	80-87	BH3 interacting domain death agonist	Homo sapiens	76-79
3038704-4	1986	Three months of nadolol therapy in migraine patients caused a significant increase in plasma ACTH and decrease in beta-EP concentrations.	Nadolol	16-23	proopiomelanocortin	Homo sapiens	93-97
3038704-4	1986	Three months of nadolol therapy in migraine patients caused a significant increase in plasma ACTH and decrease in beta-EP concentrations.	Nadolol	16-23	proopiomelanocortin	Homo sapiens	114-121
2869848-6	1986	However, using a multiple regression analysis there was a highly significant correlation between the combination of the pretreatment values of active renin, prorenin and aldosterone and the reduction in diastolic pressure with both nadolol (p less than 0.001) and metoprolol (p less than 0.003).	Nadolol	232-239	renin	Homo sapiens	150-155
2868577-1	1986	Isoprenaline, isoetharine, rimiterol, dobutamine and nadolol were investigated as substrates for purified pig-liver catechol-O-methyltransferase using a sensitive spectrophotometric assay.	Nadolol	53-60	catechol-O-methyltransferase	Sus scrofa	116-144
3905182-3	1985	Plasma concentrations of GIP tended to be higher during nadolol than placebo treatment.	Nadolol	56-63	gastric inhibitory polypeptide	Homo sapiens	25-28
2410671-0	1985	Effects of antihypertensive agents propranolol, metoprolol, nadolol, prazosin, and chlorthalidone on ACAT activity in rabbit and rat aortas and on LCAT activity in human plasma in vitro.	Nadolol	60-67	sterol O-acyltransferase 1	Oryctolagus cuniculus	101-105
2858216-4	1985	Intravenous nadolol (0.05 and 0.75 mg/kg) reduced resting PAH and inulin clearances by up to 25%.	Nadolol	12-19	phenylalanine hydroxylase	Homo sapiens	58-61
6469432-4	1984	In the hypertensive population, nadolol was effective in lowering arterial pressure at rest, and significantly reduced the levels of SAP, DAP, MAP, HR and TTI reached at the end of the HG test.	Nadolol	32-39	SH2 domain containing 1A	Homo sapiens	133-136
6469432-4	1984	In the hypertensive population, nadolol was effective in lowering arterial pressure at rest, and significantly reduced the levels of SAP, DAP, MAP, HR and TTI reached at the end of the HG test.	Nadolol	32-39	death associated protein	Homo sapiens	138-141
6136140-3	1983	Since nadolol does not possess the membrane stabilising properties of propranolol, nor is it metabolized like propranolol, the effect on TBG concentration would appear to be due to beta-blockade.	Nadolol	6-13	serpin family A member 7	Homo sapiens	137-140
6218831-0	1983	Inhibition of calmodulin-activated Ca2+-ATPase by propranolol and nadolol.	Nadolol	66-73	calmodulin 1	Homo sapiens	14-24
6218831-5	1983	Nadolol, another beta-adrenergic blocker, is also an inhibitor of calmodulin-activated Ca2+-ATPase.	Nadolol	0-7	calmodulin 1	Homo sapiens	66-76
6791883-1	1981	Nadolol, a new nonselective beta 1 and beta 2 adrenergic blocking agent, has a plasma half-life of 17 to 23 hours.	Nadolol	0-7	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	28-45
33998-9	1979	Blood pressure response was independent of the pretreatment renin levels or the change in renin induced by nadolol; it was also independent of the changes in cardiac output and heart rate but was more pronounced in patients with milder baseline hypertension.	Nadolol	107-114	renin	Homo sapiens	90-95
37878-2	1979	2 The amount of nadolol excreted during the 120-h period after receiving the drug ranged from less than 1% in functionally anephric, patients up to 11.5% in patients with average creatinine clearance of 57.9 +/- 3.6 ml/min/1.73 m2.	Nadolol	16-23	CD59 molecule (CD59 blood group)	Homo sapiens	219-224
15737-6	1977	(3) Dose-related inhibition was observed with practolol, oxprenolol, timolol, nadolol, and atenolol at concentrations ranging from 10-8 to 10-5 m. Basal renin release was significantly (P is less than 0.01) inhibited by angiotensin II at 10-6 m, which also inhibited isoproterenol-stimulated renin release in a dose-related fashion.	Nadolol	78-85	renin	Rattus norvegicus	153-158
33387374-0	2021	Urinary Excretion of Nadolol as a Possible In Vivo Probe for Drug Interactions Involving P-glycoprotein.	Nadolol	21-28	ATP binding cassette subfamily B member 1	Homo sapiens	89-103
33387374-2	2021	Previous studies have reported that nadolol is a substrate of P-glycoprotein, and the coadministration with itraconazole, a typical P-glycoprotein inhibitor, results in elevated plasma concentrations and cumulative urinary excretion of nadolol.	Nadolol	36-43	ATP binding cassette subfamily B member 1	Homo sapiens	62-76
33387374-2	2021	Previous studies have reported that nadolol is a substrate of P-glycoprotein, and the coadministration with itraconazole, a typical P-glycoprotein inhibitor, results in elevated plasma concentrations and cumulative urinary excretion of nadolol.	Nadolol	36-43	ATP binding cassette subfamily B member 1	Homo sapiens	132-146
33387374-2	2021	Previous studies have reported that nadolol is a substrate of P-glycoprotein, and the coadministration with itraconazole, a typical P-glycoprotein inhibitor, results in elevated plasma concentrations and cumulative urinary excretion of nadolol.	Nadolol	236-243	ATP binding cassette subfamily B member 1	Homo sapiens	62-76
33387374-2	2021	Previous studies have reported that nadolol is a substrate of P-glycoprotein, and the coadministration with itraconazole, a typical P-glycoprotein inhibitor, results in elevated plasma concentrations and cumulative urinary excretion of nadolol.	Nadolol	236-243	ATP binding cassette subfamily B member 1	Homo sapiens	132-146
33387374-3	2021	In this study, we assessed whether measurements of urinary-excreted nadolol can be an alternative method of plasma pharmacokinetics for P-glycoprotein-mediated drug interactions in humans.	Nadolol	68-75	ATP binding cassette subfamily B member 1	Homo sapiens	136-150
33387374-7	2021	In the drug interactions of nadolol with itraconazole, rifampicin, a well-known P-glycoprotein inducer, or grapefruit juice, there were significant correlations between the differences in AUC0-48 and those in Ae, 0-48 from the controls in individual subjects.	Nadolol	28-35	ATP binding cassette subfamily B member 1	Homo sapiens	80-94
33387374-8	2021	These results suggest that the measurements of urinary excretion of nadolol can be employed as a sensitive and reliable alternative to plasma pharmacokinetics for the evaluation of P-glycoprotein-mediated drug interactions.	Nadolol	68-75	ATP binding cassette subfamily B member 1	Homo sapiens	181-195
33611903-17	2021	Nadolol succeeded in eliminating cardiac events in one patient with LQT2 post ineffective metoprolol medication.	Nadolol	0-7	potassium voltage-gated channel subfamily H member 2	Homo sapiens	68-72
33506522-6	2021	The association was found statistically significant for nadolol [ROR (95% CI): 6.98 (5.40-9.03)], celiprolol [2.35 (1.35-4.10)], propranolol [2.14 (1.87-2.46)] and bisoprolol [1.42 (1.25-1.61)].	Nadolol	56-63	long intergenic non-protein coding RNA, regulator of reprogramming	Homo sapiens	65-68
33381033-5	2020	In conclusion, nadolol was recommended as a relatively effective strategy for LQT2 in order to improve the prognosis of patients during a long follow-up period.	Nadolol	15-22	potassium voltage-gated channel subfamily H member 2	Homo sapiens	78-82
33354416-10	2020	In addition, nadolol, a beta blocker, has also been identified in this study to bind to the EphB2-ephrinB2 complex, and the possibility of this drug treating multiple cancers is still relatively unexplored.	Nadolol	13-20	amyloid beta precursor protein	Homo sapiens	22-28
33354416-10	2020	In addition, nadolol, a beta blocker, has also been identified in this study to bind to the EphB2-ephrinB2 complex, and the possibility of this drug treating multiple cancers is still relatively unexplored.	Nadolol	13-20	EPH receptor B2	Homo sapiens	92-97
33354416-10	2020	In addition, nadolol, a beta blocker, has also been identified in this study to bind to the EphB2-ephrinB2 complex, and the possibility of this drug treating multiple cancers is still relatively unexplored.	Nadolol	13-20	ephrin B2	Homo sapiens	98-106
32518084-8	2020	An in vitro assay confirmed that NE down-regulates CCL2 production in both mouse and human macrophages, and that pre-treatment with the pan-beta-adrenergic receptor inhibitor nadolol rescues this activity.	Nadolol	175-182	chemokine (C-C motif) ligand 2	Mus musculus	51-55
33304417-6	2020	This is the first report that demonstrates the efficacy and safety of trans-maternal administration of nadolol for treatment of symptomatic LQT2 fetuses with TdP.	Nadolol	103-110	potassium voltage-gated channel subfamily H member 2	Homo sapiens	140-144
32595275-11	2020	Chronic beta-adrenergic receptor (beta-AR) blockade with nadolol abrogated stress-induced alterations in tumor burden and cleaved caspase-3 expression, lung MDSC frequency, and exosomal TGF-beta content.	Nadolol	57-64	adrenergic receptor, beta 1	Mus musculus	34-41
32595275-11	2020	Chronic beta-adrenergic receptor (beta-AR) blockade with nadolol abrogated stress-induced alterations in tumor burden and cleaved caspase-3 expression, lung MDSC frequency, and exosomal TGF-beta content.	Nadolol	57-64	caspase 3	Mus musculus	130-139
32595275-11	2020	Chronic beta-adrenergic receptor (beta-AR) blockade with nadolol abrogated stress-induced alterations in tumor burden and cleaved caspase-3 expression, lung MDSC frequency, and exosomal TGF-beta content.	Nadolol	57-64	transforming growth factor alpha	Mus musculus	186-194
32038628-8	2019	Furthermore, administering a beta1 + beta2-AR (nadolol), but not a beta1-AR (bisoprolol) antagonist prior to exercise abrogated the exercise-induced enhancement in TCR-gammadelta T-cell mobilization and ex vivo expansion.	Nadolol	47-54	AA1	Homo sapiens	27-34
32038628-8	2019	Furthermore, administering a beta1 + beta2-AR (nadolol), but not a beta1-AR (bisoprolol) antagonist prior to exercise abrogated the exercise-induced enhancement in TCR-gammadelta T-cell mobilization and ex vivo expansion.	Nadolol	47-54	adenosine A2a receptor	Homo sapiens	37-45
30912151-0	2019	A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia.	Nadolol	51-58	ryanodine receptor 2	Homo sapiens	20-24
30912151-1	2019	We report a 17-year-old boy with a large RYR2 exon 3 deletion who has a severe catecholaminergic polymorphic ventricular tachycardia (CPVT) phenotype characterized by refractoriness to both nadolol and flecainide which has previously not been reported in this subgroup of CPVT patients.	Nadolol	190-197	ryanodine receptor 2	Homo sapiens	41-45
29480324-9	2018	EGCG competitively inhibited OATP1A2-mediated uptake of sulphobromophthalein and nadolol with Ki values of 21.6 and 19.4 muM, respectively.	Nadolol	81-88	solute carrier organic anion transporter family member 1A2	Homo sapiens	29-36
29480324-9	2018	EGCG competitively inhibited OATP1A2-mediated uptake of sulphobromophthalein and nadolol with Ki values of 21.6 and 19.4 muM, respectively.	Nadolol	81-88	latexin	Homo sapiens	121-124
29210030-6	2018	Propranolol and nadolol block the beta-1 in the heart and the peripheral beta-2 adrenergic receptors.	Nadolol	16-23	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	34-40
29210030-6	2018	Propranolol and nadolol block the beta-1 in the heart and the peripheral beta-2 adrenergic receptors.	Nadolol	16-23	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	73-79
29059199-8	2017	Among the beta-blockers, nadolol showed a significant risk reduction in both LQT1 and LQT2 (HR 0.47 and 0.27, respectively), whereas atenolol and propranolol decreased the risk only in LQT1 (HR 0.36 and 0.46, respectively).	Nadolol	25-32	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	77-81
29059199-8	2017	Among the beta-blockers, nadolol showed a significant risk reduction in both LQT1 and LQT2 (HR 0.47 and 0.27, respectively), whereas atenolol and propranolol decreased the risk only in LQT1 (HR 0.36 and 0.46, respectively).	Nadolol	25-32	potassium voltage-gated channel subfamily H member 2	Homo sapiens	86-90
29059199-12	2017	Among them, nadolol was effective in LQT1 and LQT2, whereas other drugs showed different effectiveness depending on LQT genotype.	Nadolol	12-19	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	37-41
29059199-12	2017	Among them, nadolol was effective in LQT1 and LQT2, whereas other drugs showed different effectiveness depending on LQT genotype.	Nadolol	12-19	potassium voltage-gated channel subfamily H member 2	Homo sapiens	46-50
27667324-0	2017	Nadolol reduces insulin sensitivity in liver cirrhosis: a randomized double-blind crossover trial.	Nadolol	0-7	insulin	Homo sapiens	16-23
27667324-8	2017	RESULTS: Compared with placebo, nadolol treatment reduced insulin sensitivity (79.7 +- 10.1 vs 99.6 +- 10.3 muL/kg fat-free mass min-1  (mU/L)-1 , P = .005).	Nadolol	32-39	insulin	Homo sapiens	58-65
27667324-8	2017	RESULTS: Compared with placebo, nadolol treatment reduced insulin sensitivity (79.7 +- 10.1 vs 99.6 +- 10.3 muL/kg fat-free mass min-1  (mU/L)-1 , P = .005).	Nadolol	32-39	mitochondrial ubiquitin ligase activator of NFKB 1	Mus musculus	137-144
27667324-12	2017	CONCLUSIONS: Nadolol significantly worsened insulin sensitivity, glycemia, and disposition index in patients with liver cirrhosis.	Nadolol	13-20	insulin	Homo sapiens	44-51
27491078-4	2016	An individual with CPVT harboring a novel mutation in the type 2 cardiac ryanodine receptor (RyR2) was identified whose persistent ventricular arrhythmias during beta-blockade with nadolol were abolished during flecainide treatment.	Nadolol	181-188	ryanodine receptor 2	Homo sapiens	93-97
26702643-0	2016	The Nonmetabolized beta-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.	Nadolol	32-39	solute carrier family 22 member 1	Homo sapiens	58-62
26702643-0	2016	The Nonmetabolized beta-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.	Nadolol	32-39	POU class 2 homeobox 2	Homo sapiens	64-68
26702643-0	2016	The Nonmetabolized beta-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.	Nadolol	32-39	solute carrier family 47 member 1	Homo sapiens	70-75
26702643-0	2016	The Nonmetabolized beta-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.	Nadolol	32-39	solute carrier family 47 member 2	Homo sapiens	77-84
26702643-0	2016	The Nonmetabolized beta-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.	Nadolol	32-39	ATP binding cassette subfamily B member 1	Homo sapiens	90-104
26702643-0	2016	The Nonmetabolized beta-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.	Nadolol	32-39	solute carrier organic anion transporter family member 1B3	Homo sapiens	129-136
26702643-1	2016	Nadolol is a nonmetabolized beta-adrenoceptor antagonist and is a substrate of OATP1A2, but not of OATP2B1.	Nadolol	0-7	solute carrier organic anion transporter family member 1A2	Homo sapiens	79-86
26702643-3	2016	We therefore investigated nadolol as a potential substrate of the hepatic uptake transporters OATP1B1, OATP1B3, and OCT1 and of the renal transporters OCT2, MATE1, and MATE2-K expressed in HEK cells.	Nadolol	26-33	solute carrier organic anion transporter family member 1B1	Homo sapiens	94-101
26702643-3	2016	We therefore investigated nadolol as a potential substrate of the hepatic uptake transporters OATP1B1, OATP1B3, and OCT1 and of the renal transporters OCT2, MATE1, and MATE2-K expressed in HEK cells.	Nadolol	26-33	solute carrier organic anion transporter family member 1B3	Homo sapiens	103-110
26702643-3	2016	We therefore investigated nadolol as a potential substrate of the hepatic uptake transporters OATP1B1, OATP1B3, and OCT1 and of the renal transporters OCT2, MATE1, and MATE2-K expressed in HEK cells.	Nadolol	26-33	solute carrier family 22 member 1	Homo sapiens	116-120
26702643-4	2016	Moreover, the importance of P-glycoprotein (P-gp) for nadolol transport was studied using double transfected MDCK-OCT1-P-gp cells.	Nadolol	54-61	ATP binding cassette subfamily B member 1	Homo sapiens	28-42
26702643-4	2016	Moreover, the importance of P-glycoprotein (P-gp) for nadolol transport was studied using double transfected MDCK-OCT1-P-gp cells.	Nadolol	54-61	ATP binding cassette subfamily B member 1	Homo sapiens	44-48
26702643-6	2016	In contrast, a significantly higher nadolol accumulation (at 1 and 10 muM) was found in OCT1, OCT2, MATE1, and MATE2-K cells compared to control cells (P < 0.01).	Nadolol	36-43	solute carrier family 22 member 1	Homo sapiens	88-92
26702643-6	2016	In contrast, a significantly higher nadolol accumulation (at 1 and 10 muM) was found in OCT1, OCT2, MATE1, and MATE2-K cells compared to control cells (P < 0.01).	Nadolol	36-43	POU class 2 homeobox 2	Homo sapiens	94-98
26702643-6	2016	In contrast, a significantly higher nadolol accumulation (at 1 and 10 muM) was found in OCT1, OCT2, MATE1, and MATE2-K cells compared to control cells (P < 0.01).	Nadolol	36-43	solute carrier family 47 member 1	Homo sapiens	100-105
26702643-6	2016	In contrast, a significantly higher nadolol accumulation (at 1 and 10 muM) was found in OCT1, OCT2, MATE1, and MATE2-K cells compared to control cells (P < 0.01).	Nadolol	36-43	solute carrier family 47 member 2	Homo sapiens	111-116
26702643-7	2016	Km values for OCT2-, MATE1-, and MATE2-K-mediated nadolol uptake were 122, 531, and 372 muM, respectively.	Nadolol	50-57	POU class 2 homeobox 2	Homo sapiens	14-18
26702643-7	2016	Km values for OCT2-, MATE1-, and MATE2-K-mediated nadolol uptake were 122, 531, and 372 muM, respectively.	Nadolol	50-57	solute carrier family 47 member 1	Homo sapiens	21-26
26702643-7	2016	Km values for OCT2-, MATE1-, and MATE2-K-mediated nadolol uptake were 122, 531, and 372 muM, respectively.	Nadolol	50-57	solute carrier family 47 member 2	Homo sapiens	33-38
26702643-9	2016	The P-gp inhibitor zosuquidar significantly reduced basal to apical nadolol transport in monolayers of MDCK-OCT1-P-gp cells.	Nadolol	68-75	ATP binding cassette subfamily B member 1	Homo sapiens	4-8
26702643-9	2016	The P-gp inhibitor zosuquidar significantly reduced basal to apical nadolol transport in monolayers of MDCK-OCT1-P-gp cells.	Nadolol	68-75	solute carrier family 22 member 1	Homo sapiens	108-112
26702643-9	2016	The P-gp inhibitor zosuquidar significantly reduced basal to apical nadolol transport in monolayers of MDCK-OCT1-P-gp cells.	Nadolol	68-75	ATP binding cassette subfamily B member 1	Homo sapiens	113-117
26702643-10	2016	In summary, nadolol is a substrate of the cation transporters OCT1, OCT2, MATE1, MATE2-K, and of P-gp.	Nadolol	12-19	solute carrier family 22 member 1	Homo sapiens	62-66
26702643-10	2016	In summary, nadolol is a substrate of the cation transporters OCT1, OCT2, MATE1, MATE2-K, and of P-gp.	Nadolol	12-19	POU class 2 homeobox 2	Homo sapiens	68-72
26702643-10	2016	In summary, nadolol is a substrate of the cation transporters OCT1, OCT2, MATE1, MATE2-K, and of P-gp.	Nadolol	12-19	solute carrier family 47 member 1	Homo sapiens	74-79
26702643-10	2016	In summary, nadolol is a substrate of the cation transporters OCT1, OCT2, MATE1, MATE2-K, and of P-gp.	Nadolol	12-19	solute carrier family 47 member 2	Homo sapiens	81-88
26702643-10	2016	In summary, nadolol is a substrate of the cation transporters OCT1, OCT2, MATE1, MATE2-K, and of P-gp.	Nadolol	12-19	ATP binding cassette subfamily B member 1	Homo sapiens	97-101
25257637-7	2014	In LQT1, the risk reduction for first cardiac events was similar among the 4 beta-blockers, but in LQT2, nadolol provided the only significant risk reduction (hazard ratio: 0.40 [0.16 to 0.98]).	Nadolol	105-112	potassium voltage-gated channel subfamily H member 2	Homo sapiens	99-103
25257637-9	2014	CONCLUSIONS: Although the 4 beta-blockers are equally effective in reducing the risk of a first cardiac event in LQTS, their efficacy differed by genotype; nadolol was the only beta-blocker associated with a significant risk reduction in patients with LQT2.	Nadolol	156-163	potassium voltage-gated channel subfamily H member 2	Homo sapiens	252-256
24419562-6	2014	[(3)H]-Nadolol uptake assays in human embryonic kidney 293 cells stably expressing the organic anion-transporting polypeptides OATP1A2 and OATP2B1 revealed that nadolol is a substrate of OATP1A2 (Michaelis constant (K(m)) = 84.3 mumol/l) but not of OATP2B1.	Nadolol	161-168	solute carrier organic anion transporter family member 1A2	Homo sapiens	127-134
24419562-6	2014	[(3)H]-Nadolol uptake assays in human embryonic kidney 293 cells stably expressing the organic anion-transporting polypeptides OATP1A2 and OATP2B1 revealed that nadolol is a substrate of OATP1A2 (Michaelis constant (K(m)) = 84.3 mumol/l) but not of OATP2B1.	Nadolol	161-168	solute carrier organic anion transporter family member 2B1	Homo sapiens	139-146
24419562-6	2014	[(3)H]-Nadolol uptake assays in human embryonic kidney 293 cells stably expressing the organic anion-transporting polypeptides OATP1A2 and OATP2B1 revealed that nadolol is a substrate of OATP1A2 (Michaelis constant (K(m)) = 84.3 mumol/l) but not of OATP2B1.	Nadolol	161-168	solute carrier organic anion transporter family member 1A2	Homo sapiens	187-194
24419562-6	2014	[(3)H]-Nadolol uptake assays in human embryonic kidney 293 cells stably expressing the organic anion-transporting polypeptides OATP1A2 and OATP2B1 revealed that nadolol is a substrate of OATP1A2 (Michaelis constant (K(m)) = 84.3 mumol/l) but not of OATP2B1.	Nadolol	161-168	solute carrier organic anion transporter family member 2B1	Homo sapiens	249-256
24419562-7	2014	Moreover, green tea significantly inhibited OATP1A2-mediated nadolol uptake (half-maximal inhibitory concentration, IC(50) = 1.36%).	Nadolol	61-68	solute carrier organic anion transporter family member 1A2	Homo sapiens	44-51
24419562-8	2014	These results suggest that green tea reduces plasma concentrations of nadolol possibly in part by inhibition of OATP1A2-mediated uptake of nadolol in the intestine.	Nadolol	70-77	solute carrier organic anion transporter family member 1A2	Homo sapiens	112-119
24419562-8	2014	These results suggest that green tea reduces plasma concentrations of nadolol possibly in part by inhibition of OATP1A2-mediated uptake of nadolol in the intestine.	Nadolol	139-146	solute carrier organic anion transporter family member 1A2	Homo sapiens	112-119
24144049-6	2013	All experiments were performed in the presence of nadolol (a beta(1)/beta(2)-adrenoceptor antagonist).	Nadolol	50-57	adrenoceptor beta 2	Homo sapiens	69-89
23473506-4	2013	3 cm teico-CSP resulted to be effective for the on-line pre-concentration, before the separation, of acebutolol, alprenolol, nadolol, oxprenolol and terbutaline with limit of detection at levels of few ng/mL.	Nadolol	125-132	DnaJ heat shock protein family (Hsp40) member C5	Homo sapiens	11-14
23419354-1	2013	The aim of the present study was to clarify the involvement of P-glycoprotein (P-gp) or organic anion transporting polypeptide (Oatp) 1a5 in the pharmacokinetics of nadolol (NDL), a non-metabolized hydrophilic beta-adrenoceptor blocker, in rats.	Nadolol	165-172	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	63-77
23419354-1	2013	The aim of the present study was to clarify the involvement of P-glycoprotein (P-gp) or organic anion transporting polypeptide (Oatp) 1a5 in the pharmacokinetics of nadolol (NDL), a non-metabolized hydrophilic beta-adrenoceptor blocker, in rats.	Nadolol	165-172	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	79-83
23419354-2	2013	Pretreatment with itraconazole (ICZ, P-gp inhibitor, 50 mg/kg) for 30 min before oral administration of NDL (10 mg/kg) significantly increased the area under the plasma concentration-time curve (AUC0- )of NDL by 1.7-fold compared with control.	Nadolol	104-107	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	37-41
23419354-2	2013	Pretreatment with itraconazole (ICZ, P-gp inhibitor, 50 mg/kg) for 30 min before oral administration of NDL (10 mg/kg) significantly increased the area under the plasma concentration-time curve (AUC0- )of NDL by 1.7-fold compared with control.	Nadolol	205-208	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	37-41
22030895-0	2012	Nadolol block of Nav1.5 does not explain its efficacy in the long QT syndrome.	Nadolol	0-7	sodium voltage-gated channel alpha subunit 5	Homo sapiens	17-23
21964666-12	2012	In Summary, the simultaneous administration of a glucocorticosteroid and a beta2-adrenoceptor inverse agonist was more effective at reducing indexes of airway inflammation than either drug given alone; suggesting nadolol may possess "glucocorticoid-sparing" properties.	Nadolol	213-220	histocompatibility 2, O region beta locus	Mus musculus	73-80
21871614-0	2011	beta1-adrenergic receptor up-regulation induced by nadolol is mediated via signal transduction pathway coupled to alpha1-adrenergic receptors.	Nadolol	51-58	adrenergic receptor, beta 1	Mus musculus	0-25
21871614-2	2011	The present study attempted to clarify mechanisms of beta-AR up-regulation using mouse cerebral cortical neurons continuously exposed to nadolol (10 nM), a non-selective beta-AR antagonist, for 24 h. Nadolol dose-dependently induced both subtypes of beta-ARs, beta1- and beta2-ARs, which were not suppressed by protein A kinase inhibition with KT5720.	Nadolol	137-144	adrenergic receptor, beta 1	Mus musculus	53-60
21871614-2	2011	The present study attempted to clarify mechanisms of beta-AR up-regulation using mouse cerebral cortical neurons continuously exposed to nadolol (10 nM), a non-selective beta-AR antagonist, for 24 h. Nadolol dose-dependently induced both subtypes of beta-ARs, beta1- and beta2-ARs, which were not suppressed by protein A kinase inhibition with KT5720.	Nadolol	137-144	adrenergic receptor, beta 1	Mus musculus	260-280
21871614-2	2011	The present study attempted to clarify mechanisms of beta-AR up-regulation using mouse cerebral cortical neurons continuously exposed to nadolol (10 nM), a non-selective beta-AR antagonist, for 24 h. Nadolol dose-dependently induced both subtypes of beta-ARs, beta1- and beta2-ARs, which were not suppressed by protein A kinase inhibition with KT5720.	Nadolol	200-207	adrenergic receptor, beta 1	Mus musculus	53-60
21871614-2	2011	The present study attempted to clarify mechanisms of beta-AR up-regulation using mouse cerebral cortical neurons continuously exposed to nadolol (10 nM), a non-selective beta-AR antagonist, for 24 h. Nadolol dose-dependently induced both subtypes of beta-ARs, beta1- and beta2-ARs, which were not suppressed by protein A kinase inhibition with KT5720.	Nadolol	200-207	adrenergic receptor, beta 1	Mus musculus	170-177
21871614-2	2011	The present study attempted to clarify mechanisms of beta-AR up-regulation using mouse cerebral cortical neurons continuously exposed to nadolol (10 nM), a non-selective beta-AR antagonist, for 24 h. Nadolol dose-dependently induced both subtypes of beta-ARs, beta1- and beta2-ARs, which were not suppressed by protein A kinase inhibition with KT5720.	Nadolol	200-207	adrenergic receptor, beta 1	Mus musculus	260-280
21871614-7	2011	These results indicate that the nadolol-induced beta1-AR up-regulation is mediated via PKC-relating pathway via alpha1-AR activation with stabilizing beta1-AR mRNA and that the increased expression of beta2-ARs is regulated by pathways different from those for beta1-AR expression.	Nadolol	32-39	adrenergic receptor, beta 1	Mus musculus	48-56
21871614-7	2011	These results indicate that the nadolol-induced beta1-AR up-regulation is mediated via PKC-relating pathway via alpha1-AR activation with stabilizing beta1-AR mRNA and that the increased expression of beta2-ARs is regulated by pathways different from those for beta1-AR expression.	Nadolol	32-39	adrenergic receptor, beta 1	Mus musculus	150-158
21871614-7	2011	These results indicate that the nadolol-induced beta1-AR up-regulation is mediated via PKC-relating pathway via alpha1-AR activation with stabilizing beta1-AR mRNA and that the increased expression of beta2-ARs is regulated by pathways different from those for beta1-AR expression.	Nadolol	32-39	hemoglobin, beta adult minor chain	Mus musculus	201-206
21871614-7	2011	These results indicate that the nadolol-induced beta1-AR up-regulation is mediated via PKC-relating pathway via alpha1-AR activation with stabilizing beta1-AR mRNA and that the increased expression of beta2-ARs is regulated by pathways different from those for beta1-AR expression.	Nadolol	32-39	adrenergic receptor, beta 1	Mus musculus	150-158
21225244-0	2011	The effects of acute and chronic nadolol treatment on beta2AR signaling in HEK293 cells.	Nadolol	33-40	adrenoceptor beta 2	Homo sapiens	54-61
21225244-4	2011	In this study, we examined the effects of nadolol on beta(2)AR levels and signaling components downstream of the beta(2)AR using a line of HEK293 cells expressing human beta(2)ARs.	Nadolol	42-49	adrenoceptor beta 2	Homo sapiens	53-62
21225244-5	2011	Chronic treatment with NAD increased beta(2)AR protein levels and decreased receptor degradation, consistent with receptor stabilization by the inverse agonist.	Nadolol	23-26	adrenoceptor beta 2	Homo sapiens	37-46
21225244-7	2011	A 5-min treatment with NAD decreased forskolin-stimulated phosphorylation at the beta(2)AR PKA site Ser 262 while a 24-h treatment with NAD increased it.	Nadolol	23-26	adrenoceptor beta 2	Homo sapiens	81-90
21225244-10	2011	Chronic NAD treatment therefore increases cellular cAMP levels by mechanisms that include the upregulation of beta(2)AR and G(alpha)s. This effect may explain in part the beneficial effects of chronic nadolol treatment on airway contractility.	Nadolol	8-11	adrenoceptor beta 2	Homo sapiens	110-119
21225244-10	2011	Chronic NAD treatment therefore increases cellular cAMP levels by mechanisms that include the upregulation of beta(2)AR and G(alpha)s. This effect may explain in part the beneficial effects of chronic nadolol treatment on airway contractility.	Nadolol	201-208	adrenoceptor beta 2	Homo sapiens	110-119
20637193-5	2010	In both strains, relaxation to celiprolol was decreased in the presence of nadolol (a beta(1)/beta(2)-adrenoceptor antagonist, 10 microM).	Nadolol	75-82	adrenoceptor beta 2	Rattus norvegicus	94-114
20369594-5	2010	The selective beta-3 adrenoceptor agonist BRL 37344 at high concentrations (10(-6) - 10(-5) M) produced a coronary vasodilator effect, but this effect was completely blocked by the beta-1/beta-2 adrenoceptor antagonist nadolol (10(-5) M).	Nadolol	219-226	adrenergic receptor, beta 3	Mus musculus	14-33
20369594-5	2010	The selective beta-3 adrenoceptor agonist BRL 37344 at high concentrations (10(-6) - 10(-5) M) produced a coronary vasodilator effect, but this effect was completely blocked by the beta-1/beta-2 adrenoceptor antagonist nadolol (10(-5) M).	Nadolol	219-226	hemoglobin, beta adult major chain	Mus musculus	181-187
20369594-5	2010	The selective beta-3 adrenoceptor agonist BRL 37344 at high concentrations (10(-6) - 10(-5) M) produced a coronary vasodilator effect, but this effect was completely blocked by the beta-1/beta-2 adrenoceptor antagonist nadolol (10(-5) M).	Nadolol	219-226	adrenergic receptor, beta 2	Mus musculus	188-207
19893132-3	2009	15 mg/kg of Nadolol (the dose sufficient to prevent CRH-induced increases in heart-rate for 2 hr), dissolved in saline was administered intraperitoneally, 30 minutes prior to CRH (The dose of interest for CRH - 1 mkg/kg - was determined earlier, as provoking the maximal increase of plasma corticosterone level after 20 minutes of its ICV injection).	Nadolol	12-19	corticotropin releasing hormone	Rattus norvegicus	52-55
19893132-7	2009	Thus, according our results, 30 min after injection, the dose of Nadolol, sufficient to prevent CRH-induced increase in heart rate, doesn"t preclude the CRH-induced increase of plasma corticosterone - one of key signs of the stress-axis activation.	Nadolol	65-72	corticotropin releasing hormone	Rattus norvegicus	96-99
19159673-7	2009	Similarly, pre-treatment of mice with the peripherally acting beta-adrenoceptor antagonist nadolol completely blocked the stress-induced increase in IL-10 and IL-19 mRNA expression.	Nadolol	91-98	interleukin 10	Mus musculus	149-154
19159673-7	2009	Similarly, pre-treatment of mice with the peripherally acting beta-adrenoceptor antagonist nadolol completely blocked the stress-induced increase in IL-10 and IL-19 mRNA expression.	Nadolol	91-98	interleukin 19	Mus musculus	159-164
17689526-8	2007	Consistent with a role for beta-adrenoceptor activation in the immunosuppressive actions of MDMA, pre-treatment with the beta-adrenoceptor antagonist nadolol blocked the MDMA-induced increase in IL-10, and also inhibited the suppressive action of MDMA on the innate IFN-gamma response.	Nadolol	150-157	interleukin 10	Mus musculus	195-200
17689526-8	2007	Consistent with a role for beta-adrenoceptor activation in the immunosuppressive actions of MDMA, pre-treatment with the beta-adrenoceptor antagonist nadolol blocked the MDMA-induced increase in IL-10, and also inhibited the suppressive action of MDMA on the innate IFN-gamma response.	Nadolol	150-157	interferon gamma	Mus musculus	266-275
17622774-6	2007	Selective beta(3)-adrenoceptor agonist, BRL37344 ([4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid), caused biphasic relaxation which was not affected by nadolol (1 micromol/l).	Nadolol	180-187	adrenoceptor beta 3	Rattus norvegicus	10-30
16920085-1	2006	Mechanisms of up-regulation of beta-adrenergic receptors (beta-ARs) induced by sustained exposure to 10(-8) M nadolol, a non-selective beta-AR antagonist, were examined using mouse cerebrocortical neurons.	Nadolol	110-117	adrenergic receptor, beta 1	Mus musculus	58-65
16920085-8	2006	During 24 h after nadolol exposure, the increase in proteins of beta1- and beta2-ARs in the neuronal membrane was due to the increased receptor protein translocation from cytosol to membrane.	Nadolol	18-25	hemoglobin, beta adult major chain	Mus musculus	64-80
16135702-7	2005	Inhibition was abolished by the beta3-AR antagonist (S)-N-[4-[2-[[3-[3-(acetamidomethyl)phenoxy]-2-hydroxypropyl]amino]ethyl]phenyl]benzenesulfonamide (L-748,337; 10(-6) M), but not by nadolol.	Nadolol	185-192	adrenoceptor beta 3	Homo sapiens	32-40
15935613-12	2005	RU486 and nadolol treatment also tended to decrease IL-10, IFN-gamma, TNFalpha (nadolol only), and IL-1beta (RU486 only) in both exercise and control mice, suggesting that stress hormones may be necessary during infection for optimal responsiveness.	Nadolol	10-17	interleukin 10	Mus musculus	52-57
15935613-12	2005	RU486 and nadolol treatment also tended to decrease IL-10, IFN-gamma, TNFalpha (nadolol only), and IL-1beta (RU486 only) in both exercise and control mice, suggesting that stress hormones may be necessary during infection for optimal responsiveness.	Nadolol	10-17	interferon gamma	Mus musculus	59-68
15935613-12	2005	RU486 and nadolol treatment also tended to decrease IL-10, IFN-gamma, TNFalpha (nadolol only), and IL-1beta (RU486 only) in both exercise and control mice, suggesting that stress hormones may be necessary during infection for optimal responsiveness.	Nadolol	10-17	tumor necrosis factor	Mus musculus	70-78
15935613-12	2005	RU486 and nadolol treatment also tended to decrease IL-10, IFN-gamma, TNFalpha (nadolol only), and IL-1beta (RU486 only) in both exercise and control mice, suggesting that stress hormones may be necessary during infection for optimal responsiveness.	Nadolol	10-17	interleukin 1 beta	Mus musculus	99-107
15652410-7	2005	Whilst pre-treatment with nadolol completely blocked the stress-induced increase in IL-10, it failed to alter the suppression of TNF-alpha or IL-1beta.	Nadolol	26-33	interleukin 10	Rattus norvegicus	84-89
15595859-7	2004	Zonal displacement chromatography using CGP 12177A as the marker and racemic mixtures of the antagonists nadolol and propranolol demonstrated that the immobilized beta(2)-AR retained its ability to specifically bind these compounds.	Nadolol	105-112	adrenoceptor beta 2	Homo sapiens	163-173
15145613-4	2004	Furthermore, MP inhibition of granzyme B mRNA was blocked by the beta-antagonist nadolol.	Nadolol	81-88	granzyme B	Homo sapiens	30-40
15069206-5	2004	In comparison with nontreated asthmatic mice, we observed that: (i) The beta-AR antagonists nadolol or carvedilol, given as a single i.v.	Nadolol	92-99	adrenergic receptor, beta 1	Mus musculus	72-79
15069206-7	2004	(ii) Chronic treatment with nadolol or carvedilol significantly increased beta-AR densities in lung membranes by 719% and 828%, respectively.	Nadolol	28-35	adrenergic receptor, beta 1	Mus musculus	74-81
12909312-10	2003	Pretreatment with nadolol, a beta(1)/beta(2)-AR blocker, blunted the rebound in peak tension elicited by beta(3)-AR agonists suggesting a non-specific action of these compounds on beta(1)- and beta(2)-AR.	Nadolol	18-25	adrenergic receptor, beta 2	Mus musculus	37-47
12909312-10	2003	Pretreatment with nadolol, a beta(1)/beta(2)-AR blocker, blunted the rebound in peak tension elicited by beta(3)-AR agonists suggesting a non-specific action of these compounds on beta(1)- and beta(2)-AR.	Nadolol	18-25	adrenergic receptor, beta 3	Mus musculus	105-115
12909312-10	2003	Pretreatment with nadolol, a beta(1)/beta(2)-AR blocker, blunted the rebound in peak tension elicited by beta(3)-AR agonists suggesting a non-specific action of these compounds on beta(1)- and beta(2)-AR.	Nadolol	18-25	adrenergic receptor, beta 2	Mus musculus	193-203
12445584-9	2002	However, the ability of fenfluramine to suppress tumor necrosis factor-alpha production cannot be accounted for by increased interleukin-10 production, as pretreatment with the beta-adrenoceptor antagonist nadolol completely blocked the increase in interleukin-10 without altering the suppression of tumor necrosis factor-alpha induced by fenfluramine.	Nadolol	206-213	tumor necrosis factor	Rattus norvegicus	49-76
12445584-9	2002	However, the ability of fenfluramine to suppress tumor necrosis factor-alpha production cannot be accounted for by increased interleukin-10 production, as pretreatment with the beta-adrenoceptor antagonist nadolol completely blocked the increase in interleukin-10 without altering the suppression of tumor necrosis factor-alpha induced by fenfluramine.	Nadolol	206-213	interleukin 10	Rattus norvegicus	249-263
12445584-9	2002	However, the ability of fenfluramine to suppress tumor necrosis factor-alpha production cannot be accounted for by increased interleukin-10 production, as pretreatment with the beta-adrenoceptor antagonist nadolol completely blocked the increase in interleukin-10 without altering the suppression of tumor necrosis factor-alpha induced by fenfluramine.	Nadolol	206-213	tumor necrosis factor	Rattus norvegicus	300-327
11908922-3	2002	We tested whether blocking SNS activity using 6-OHDA or the beta-receptor antagonist nadolol alters the typical pattern in production of T helper 1 (Th1) and Th2 cytokines seen in cultures of spleen cells from C57BL/6 mice infected with murine AIDS (MAIDS).	Nadolol	85-92	heart and neural crest derivatives expressed 2	Mus musculus	158-161
11824942-4	2001	Furthermore, (+/-)-nadolol, which belongs to the aryloxypropanolamine class and has beta1- and beta2-adrenoceptor antagonistic characteristics, displays agonistic activity at beta3-adrenoceptors.	Nadolol	13-26	beta-2 adrenergic receptor	Cavia porcellus	84-113
11292254-7	2001	In nadolol-treated old mice, the frequency of the immature CD4-8- population was increased, and the intermediate CD4+8+ population was reduced.	Nadolol	3-10	CD4 antigen	Mus musculus	59-62
11292254-7	2001	In nadolol-treated old mice, the frequency of the immature CD4-8- population was increased, and the intermediate CD4+8+ population was reduced.	Nadolol	3-10	CD4 antigen	Mus musculus	113-116
11292254-10	2001	The percentage of CD8+44low naive cells in peripheral blood increased in nadolol-treated mice, suggesting that more CD4-8+ cells were exported from the thymus to the periphery.	Nadolol	73-80	CD4 antigen	Mus musculus	116-119
10808734-8	2000	Eleven patients (group VIII) received nadolol in a dose of 40-80 mg daily for two weeks.	Nadolol	38-45	cytochrome c oxidase subunit 8A	Homo sapiens	23-27
10644643-5	2000	Pretreatment of rats with the beta-adrenergic receptor antagonist nadolol also prevented OT-induced renin secretion.	Nadolol	66-73	renin	Rattus norvegicus	100-105
10644643-6	2000	Similarly, nadolol injected during infusion of OT markedly reduced the elevated plasma renin levels.	Nadolol	11-18	renin	Rattus norvegicus	87-92
10498836-7	1999	In the presence of nadolol, a beta1- and beta2-adrenoceptor antagonist, isoprenaline-induced relaxation persisted (Emax=55.6+/-5.3%), but occurred at higher concentrations (pD2=6.71+/-0.10) than in the absence of nadolol and lasted longer.	Nadolol	19-26	adrenoceptor beta 2	Rattus norvegicus	41-59
10037693-10	1999	When the expression level of beta3-adrenoceptor was lowered, CFTR was not activated under base-line conditions but became sensitive to beta3-adrenoceptor stimulation (isoproterenol plus nadolol, SR 58611, or CGP 12177).	Nadolol	186-193	adrenoceptor beta 3	Homo sapiens	29-47
10037693-10	1999	When the expression level of beta3-adrenoceptor was lowered, CFTR was not activated under base-line conditions but became sensitive to beta3-adrenoceptor stimulation (isoproterenol plus nadolol, SR 58611, or CGP 12177).	Nadolol	186-193	CF transmembrane conductance regulator	Homo sapiens	61-65
9878736-8	1999	The effect of IL-1beta on lung clearance was blocked by pretreatment with the beta-adrenergic antagonist, nadolol (0.5 mg/kg), but not by the alpha-antagonist phentolamine (5 mg/kg).	Nadolol	106-113	interleukin 1 beta	Rattus norvegicus	14-22
9299058-3	1997	Nadolol attenuated the 2-DG-induced suppression of splenic T-cell mitogenic response and interferon-gamma production and increased nitric oxide production by macrophages in a dose-dependent manner.	Nadolol	0-7	interferon gamma	Rattus norvegicus	89-105
9126981-6	1997	IgG2a inhibition was prevented by addition of the betaAR antagonist nadolol or exogenous IFN-gamma.	Nadolol	68-75	immunoglobulin heavy variable V1-9	Mus musculus	0-5
8755668-4	1996	In the presence of nadolol, a beta1- and beta2-adrenoceptor antagonist, isoprenaline produced consistent negative inotropic effects.	Nadolol	19-26	adrenoceptor beta 2	Homo sapiens	41-59
8738584-24	1996	Nadolol blocked the open field-induced rise in plasma IL-6 only when injected i.c.v.	Nadolol	0-7	interleukin 6	Rattus norvegicus	54-58
8574280-7	1995	CONCLUSION: All three beta-adrenoceptor subtypes (beta 1, beta 2 and beta 3) may be involved in ephedrine-induced thermogenesis, but the resistance to complete inhibition by the non-selective antagonist nadolol indicates that at least 40% of the response is mediated by an atypical receptor, which is presumed to be the beta 3-adrenoceptor.	Nadolol	203-210	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	50-56
8574280-7	1995	CONCLUSION: All three beta-adrenoceptor subtypes (beta 1, beta 2 and beta 3) may be involved in ephedrine-induced thermogenesis, but the resistance to complete inhibition by the non-selective antagonist nadolol indicates that at least 40% of the response is mediated by an atypical receptor, which is presumed to be the beta 3-adrenoceptor.	Nadolol	203-210	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	58-75
7557820-12	1995	However, nadolol totally blunted the increase in insulin (15%) and free-fatty acids (4%) plasma levels.	Nadolol	9-16	insulin	Canis lupus familiaris	49-56
7981009-0	1994	The effects of lower than conventional doses of oral nadolol on relative beta 1/beta 2-adrenoceptor blockade.	Nadolol	53-60	adrenoceptor beta 1	Homo sapiens	73-99
7981009-2	1994	The aim of the present study was to evaluate the relative beta 1/beta 2 antagonist selectivity of the beta-adrenoceptor blocker nadolol, in lower than conventional clinical doses.	Nadolol	128-135	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	58-64
7981009-2	1994	The aim of the present study was to evaluate the relative beta 1/beta 2 antagonist selectivity of the beta-adrenoceptor blocker nadolol, in lower than conventional clinical doses.	Nadolol	128-135	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	65-71
7981009-8	1994	Nadolol produced dose-related reductions in exercise tachycardia in keeping with increasing beta 1-adrenoceptor blockade; mean % reduction (95% CI) compared with placebo: N5 10.7 (6.6 to 14.8), N20 21.4 (17.3 to 25.4), N80 38.9 (34.8 to 42.9).	Nadolol	0-7	adrenoceptor beta 1	Homo sapiens	92-111
7981009-9	1994	However, even the lowest dose of nadolol (5 mg) produced almost complete blunting of beta 2-mediated effects and significantly increase exercise hyperkalaemia; peak exercise hyperkalaemia (mmol l-1) (means and 95% CI): PL 4.88 (4.68 to 5.07), N5 5.36 (5.17 to 5.55), N20 5.48 (5.28 to 5.67), N80 5.42 (5.22 to 5.61).	Nadolol	33-40	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	85-91
7981009-10	1994	beta 2:beta 1 selectivity ratios significantly increased as the dose of nadolol was reduced.	Nadolol	72-79	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	0-13